Other · developed by Mereo BioPharma
BGS649 is an investigational agent studied in endometriosis and obese hypogonadotropic hypogonadism.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT01200862 | Phase 2 | Obese Hypogonadotropic Hypogonadism | Terminated | MREO |
| NCT01190475 | Phase 2 | Endometriosis | Completed | MREO |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
EndometriosisObese Hypogonadotropic Hypogonadism
See MREO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
MREO catalysts and pipeline →